Akthelia Pharma

16/06/2025

We're thrilled to be at the International Bio Convention in Boston this week in Boston to present our pioneering work towards safer and more effective cancer therapies. Come and meet us at

10/03/2025

Things are moving fast here at Akthelia and we need more hands on deck! Akthelia is looking for an R&D Manager. Our lead AKT-011 programme, a small molecule, orally available NCE, is targeting the very large opportunity to improve outcomes in cancer chemotherapy and we have IP around a broad class of compound with potential application to many areas of medicine with high unmet need. Our approach is to upregulate the innate immunology of epithelial surfaces. AKT-011 is in late pre-clinical stage, we plan to start human studies in 2026. Link in comments.

20/11/2024

Scientists are working on an ambitious plan to map all 37 trillion cells in the human body which is transforming our understanding of how our bodies work.

A new cell type, called a gut metaplastic cell seems to play a role in exacerbating inflammation in the seven million people that live with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.

Scientists are mapping out the 37 trillion cells of the human body and changing what we thought we knew

18/11/2024

If you missed the original article, here it is, no longer behind the paywall.

„Búið er að sýna fram á það, bæði í mönnum og dýrum, að þetta lífmerki, amínósýrur í blóði, er mjög góð vísbending um ástand þekjunnar í meltingarvegi,“ segir framkvæmdastjóri Akthelia.

13/11/2024

We're making exciting progress at Akthelia! We’re on a mission to transform cancer treatment side effects with innovative therapies that strengthen the body’s natural barriers. Read about our efforts to secure funding for clinical trials aimed at bringing these breakthroughs to patients by 2032.

08/04/2024

Akthelia Pharmaceuticals is thrilled to announce its receipt of the European Commission Seal of Excellence. This distinguished award underscores the high quality and potential impact of Akthelia's project proposals within the Horizon Europe program framework.

READ MORE: https://www.aktheliapharma.com/post/akthelia-receives-european-commission-seal-of-excellence

AKTHELIA PHARMACEUTICALS - Leading the sciences of our surfaces - A first-in-class therapeutic strategy upregulating the immune status of epithelial surfaces to tackle the causal pathogenesis of major disease.

08/04/2024

29/11/2023

Meet us at Nordic Life Sciences Days